Efficacy and Tolerability of the Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins

Hyperpigmentation Clinical Trial

Official title: Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo

Status Recruiting

Clinical Trial Summary

The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.

Clinical Trial Description

Hyperpigmentation is a common skin condition in which the color of the skin becomes darker. These changes result from an excess of melanin production, distribution, or transport which can be caused by various internal or external factors such as genetic predisposition, hormonal changes, inflammation, acne, ultraviolet (UV) exposure.

Typical hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma and solar lentigos.

This open, single-centre, three arm study is carried out with a new cosmetic formulation developed with the aim of acting on facial hyperpigmentation and used under normal conditions of use with before/after comparisons.

This clinical trial is conducted in accordance with the protocol, the HELSINKI declaration (1964) and subsequent amendments, and/or the International Council on Harmonization (ICH) Good Clinical Practices (GCP) / and in compliance with applicable regulatory requirements.

Statistical analysis:

• Efficacy analysis: In each group, the quantitative parameters will be analyzed using a mixed-effect model. This model includes Time and baseline as fixed effects. Patient will be added as random effect. The comparisons between post-baseline time-point and baseline will be performed whatever the interaction results using a Dunnett adjustment. Degrees of freedom for the comparisons will be approximated by the Kenward-Roger method.

• Safety analysis: No statistical analysis will be performed on safety. The data will be presented descriptively.

Categorical data will be summarized using the number and percentage of patients in each category. Continuous data will be summarized using the arithmetic mean, Standard Deviation (SD), Q1, Q3, minimum, median and maximum values.

Regarding the sample size determination, there was no formal calculation. A number of 24 patients in each group was considered sufficient to meet the study objective. ;

Related Conditions & MeSH terms

• Hyperpigmentation

• NCT number: NCT06253455
• Study type: Interventional
• Source: Cosmetique Active International
• Contact: Min HU
• Phone: 15172249746
• Email: Humin@cosderma.cn
• Status: Recruiting
• Phase: N/A
• Start date: November 13, 2023
• Completion date: March 5, 2024